Drug Trial Radar · NCT03127514
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Jun 22, 2017
Primary completion
Sep 25, 2019
Study completion Nov 24, 2019
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ALS Finding a Cure; ALS Association; Northeast ALS Consortium; Neurological Clinical Research Institute at Massachusetts General Hospital; Leandro P. Rizzuto Foundation
- First posted
- Apr 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
Conditions
- Amyotrophic Lateral Sclerosis
- Motor Neuron Disease
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Nervous System Diseases
- Central Nervous System Diseases
Interventions
AMX0035Drug
AMX0035
PlaceboOther
Matching Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope ChangeTime frame: 24 Weeks
- Number of Participants With Adverse EventsTime frame: 24 Weeks
- Number of Participants in Each Group Able to Remain on Study Drug Until Planned DiscontinuationTime frame: 24 weeks
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
UC Irvine Medical Center
Orange, California
Forbes Norris MDA/ALS Research Center - California Pacific Medical Center
San Francisco, California
University of Florida Medical Center
Gainesville, Florida
Carol and Frank Morsini Center for Advanced Health Care - University of South Florida
Tampa, Florida
Emory University Hospital
Atlanta, Georgia
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kentucky Medical Center
Lexington, Kentucky
Ochsner Neuroscience Institute
New Orleans, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
Washington University Medical Center
St Louis, Missouri
Neurology Associates P.C.
Lincoln, Nebraska
Mount Sinai Beth Israel
New York, New York
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
The Penn Comprehensive ALS Center
Philadelphia, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
Texas Neurology, P.A.
Dallas, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
ALS Center at the Swedish Neuroscience Institute
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.